MB
MBRX.US Moleculin Biotech Inc
- Market cap
- USD 8.02M
- P/E
- 0.0x
- P/B
- 0.69x
- ROE
- -248.2%
- Dividend yield
- 1.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MBRX.US undervalued?
Graham numberThe Graham number of Moleculin Biotech Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Moleculin Biotech Inc fundamental analysis
No fundamental analysis for Moleculin Biotech Inc yet.
Moleculin Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription mo…
Full company profileMoleculin Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Moleculin Biotech Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -6.16K | -18.0K | -68.0K | -185K | -285K | -260K | -222K | -127K | -126K | -90.0K | - |
| Operating Income | -3.88M | -8.65M | -15.0M | -17.5M | -19.7M | -23.0M | -30.6M | -29.6M | -26.6M | -25.1M | -29.4M |
| EBITDA | -3.88M | -8.64M | -15.0M | -13.2M | -19.5M | -15.7M | -28.9M | -29.6M | -21.6M | -33.5M | -36.0M |
| Net Income | -3.93M | -9.81M | -11.9M | -13.2M | -17.4M | -15.9M | -29.0M | -29.8M | -21.8M | -33.6M | -36.0M |
| EPS | -18,011 | -23,741 | -20,618 | -14,591 | -13,218 | -4,436 | -7,610 | -7,535 | -3,160 | -567 | -47 |
| Balance Sheet | |||||||||||
| Total Assets | 16.4M | 19.5M | 19.6M | 25.2M | 29.2M | 84.1M | 57.4M | 38.2M | 16.9M | 22.1M | 20.7M |
| Total Liabilities | 1.43M | 2.37M | 5.31M | 9.66M | 11.3M | 5.10M | 5.23M | 12.1M | 10.9M | 7.12M | 6.25M |
| Shareholders' Equity | 15.0M | 17.1M | 14.3M | 15.6M | 17.9M | 79.0M | 52.2M | 26.1M | 5.98M | 15.0M | 14.5M |
| Cash & Short-term Investments | 5.01M | 7.71M | 7.13M | 10.7M | 15.2M | 70.9M | 43.1M | 23.6M | 4.28M | 8.88M | 7.29M |
| Total Debt | 296K | - | - | 379K | 277K | 159K | 451K | 574K | 478K | 359K | 257K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.76M | -7.32M | -12.2M | -17.2M | -17.8M | -19.0M | -27.6M | -24.1M | -23.9M | -22.7M | -29.0M |
| Capital Expenditure | 21.5K | 28.0K | 417K | 52.0K | 376K | 19.0K | 67.0K | 124K | 13.0K | 0.00 | 0.00 |
| Free Cash Flow | -3.79M | -7.35M | -12.6M | -17.3M | -18.1M | -19.0M | -27.7M | -24.2M | -23.9M | -22.7M | -29.0M |
| Ratios | |||||||||||
| ROE | -26.2% | -57.3% | -83.2% | -84.8% | -97.0% | -20.1% | -55.6% | -114.2% | -364.0% | -223.6% | -248.2% |
| ROA | -24.0% | -50.3% | -60.6% | -52.3% | -59.5% | -18.9% | -50.5% | -77.9% | -128.6% | -151.7% | -173.4% |
| Net Profit Margin | - | -108,944.4% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | 0.02x | - | - | 0.02x | 0.02x | 0.00x | 0.01x | 0.02x | 0.08x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Moleculin Biotech Inc dividends
- Dividend yield
- 1.30%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 104K | 1.76 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 20, 2026.
Who owns Moleculin Biotech Inc
- Insiders 7.19%
- Institutions 9.63%
- Public & others 83.19%
- Shares outstanding 1.02M
- Free float 914K
Top funds holding MBRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 56.1K | 0.29% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 7.99K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 4.48K | 0.02% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 915.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding MBRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 47.3K | 0.23% | +46.16% | Jun 2026 |
| Vanguard Capital Management, LLC | 42.2K | 0.21% | +204.38% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 29.9K | 0.15% | +392.14% | Jun 2026 |
| XTX Topco Ltd | 22.9K | 0.11% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 20.0K | 0.10% | +55,555.56% | Jun 2026 |
| Rockefeller Capital Management L.P. | 15.0K | 0.07% | +239.29% | Jun 2026 |
| Tower Research Capital LLC | 3.51K | 0.02% | +91.50% | Jun 2026 |
| Citigroup Inc | 2.67K | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 621.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 491.00 | 0.00% | 0.00% | Jun 2026 |
| EFG International AG | 434.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 360.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 200.00 | 0.00% | 0.00% | Jun 2026 |
| Newbridge Financial Services Group, Inc. | 114.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 44.00 | 0.00% | +2.33% | Jun 2026 |
| Danske Bank A/S. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| CVA Family Office, LLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Moleculin Biotech Inc company profile
- Company name
- Moleculin Biotech Inc
- Ticker
- MBRX.US
- Exchange
- USA Stocks
- Listed since
- Jun 2, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 5300 Memorial Drive, Houston, TX, United States, 77007
- Phone
- 713 300 5160
- Website
- moleculin.com
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Moleculin Biotech Inc management
5- Mr. Walter V. KlempChairman, President & CEO · born 1960
- Mr. Jonathan P. Foster CPAExecutive VP & CFO · born 1964
- Dr. Donald H. Picker Ph.D.Chief Scientific Officer · born 1946
- Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
- Dr. John Paul Waymack M.D., Sc.D.Senior Chief Medical Officer · born 1952